BCHE and vascular dementia: This study targeted symptoms in a specific dementia subtype, that in theory might be ameliorated by this approach, and used appropriate outcome measures.Awareness is infrequently assessed in dementia drug trials.See below for current dose and indications belowa (British National Formulary April 2025).Currently no Food and Drug Administration approval for cholinesterase inhibitors in vascular dementia [86]. Relatively well tolerated but no consistent evidence that improves global functioning.